Action TNGX TANGO THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Tango Therapeutics, Inc.

Actions

TNGX

US87583X1090

Temps réel estimé Cboe BZX
Autres places de cotation
 17:57:48 11/06/2024 		Varia. 5j. Varia. 1 janv.
7,025 USD -1,89 % Graphique intraday de Tango Therapeutics, Inc. -1,26 % -28,99 %
28/05 TANGO THERAPEUTICS, INC. : HC Wainwright reste à l'achat ZM
24/05 TANGO THERAPEUTICS, INC. : Guggenheim toujours positif ZM

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Tango Therapeutics : Corporate Presentation
PU
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
BU
Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
PR
Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
AQ
Tango Therapeutics : Corporate Presentation
PU
Tango Therapeutics Announces Discontinuation of TNG348 Program
BU
Tango Therapeutics : Corporate Presentation
PU
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
BU
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
BU
Tango Therapeutics to Participate in Upcoming Investor Conferences
BU
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
AQ
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
AQ
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study
PR
Medivir's licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study
AQ
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers
AQ
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting
AQ
Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights
AQ
Tango Therapeutics to Present at the Jefferies London Healthcare Conference
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action TNGX
  4. Actualités Tango Therapeutics, Inc.
  5. Communiqués